Fierce Pharma Asia—Akeso, Summit's Keytruda-beating data; BIOSECURE's House passage; Candid's $370M debut
Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The BIOSECURE Act sailed through a full House vote despite some objections. Candid Therapeutics amassed $370 million in series A …